Robertson, Kenneth E

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 266

Effect of once‐weekly dulaglutide on glycated haemoglobin ( HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 98

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 89